Safety, tolerability, pharmacokinetics, and pharmacodynamic properties of the GPR40 agonist TAK-875: results from a double-blind, placebo-controlled single oral dose rising study in healthy volunteers.

@article{Naik2012SafetyTP,
  title={Safety, tolerability, pharmacokinetics, and pharmacodynamic properties of the GPR40 agonist TAK-875: results from a double-blind, placebo-controlled single oral dose rising study in healthy volunteers.},
  author={Himanshu Naik and Majid Vakilynejad and Jingtao Wu and Prabhakar Viswanathan and Nobuhito Dote and Tomoaki Higuchi and Eckhard Leifke},
  journal={Journal of clinical pharmacology},
  year={2012},
  volume={52 7},
  pages={1007-16}
}
TAK-875 is a selective G-protein-coupled receptor 40 agonist in development for the treatment of type 2 diabetes mellitus. This randomized, double-blind, placebo-controlled study evaluated the safety, tolerability, pharmacokinetics, and pharmacodynamics of TAK-875 following administration of a single oral dose of TAK-875 (25-800 mg) in 60 healthy volunteers. TAK-875 was eliminated slowly with a mean terminal elimination t(1/2) of approximately 28.1 to 36.6 hours. Systemic exposure of TAK-875… CONTINUE READING
31 Citations
0 References
Similar Papers

Citations

Publications citing this paper.
Showing 1-10 of 31 extracted citations

Similar Papers

Loading similar papers…